Theratechnologies Inc T.TH

Alternate Symbol(s): THTX

Healthcare Biotechnology

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. It blocks viral entry into host cells while preserving normal immunologic function. The Company is also investigating an intramuscular method of administration of Trogarzo. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy.

TSX:TH - Post by User

Theratechnologies Inc > New Press Release - Theratechnologies Draws Down on US$20 Million Second Tranche Under its Term Loan Facility With Affiliates of Marathon Asset Management

<< Previous

Bullboard Posts

Next >>

Comment by palinc2000on Jun 22, 2023 9:25am

106 Views

Post# 35508830

RE:RE:New Press Release - Theratechnologies Draws Down on US$20 Million Second Tranche Under its Term Loan Facility With Affiliates of Marathon Asset Management

At minimum they need of course to have some confidence but also I dont think they are in a position to go beyond that ...low confidence at most ....medium to high confidence very unlikely without more data in humans imo

SPCEO1 wrote: While this was expected, it is good to see it completed. Depending on sales, they likely will have in the neighborhood of $17 million of cash left after the convert is paid off.

That assumes no additional cost cutting and no money raised via the ATM. We can likely judge their confidence level on the outcome of the restarted trial by when they look to raise additional funds and how much they do raise when they do look to add to their cash position.
PressRelease wrote:
Proceeds to Be Used to Redeem All of the Outstanding 5.75% Convertible Unsecured Senior Notes This news release constitutes a designated news release for the purposes of the Companys prospectus supplement dated December 16, 2021 to its short form base shelf prospectus dated December 14...read article.